WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announces that more than 60 abstracts featuring data from its ongoing clinical development program for Jakafi® (ruxolitinib) will be presented at the upcoming American Society of Hematology (ASH) 57th Annual Meeting December 5-8, 2015 in Orlando, FL.
